Wedbush Securities’s United Therapeutics UTHR Stock Holding History

Wedbush Securities’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-2,310	Closed	-$280K	–	1019
2020 Q2	$280K	Hold	2,310	–	–	0.03%	637
2020 Q1	$219K	Sell	2,310 -1,000	-30%	-$95K	0.03%	645
2019 Q4	$292K	Sell	3,310 -700	-17%	-$61.6K	0.03%	690
2019 Q3	$320K	Sell	4,010 -200	-5%	-$16.1K	0.03%	612
2019 Q2	$329K	Buy	4,210 +700	+20%	+$65.5K	0.03%	595
2019 Q1	$412K	Sell	3,510 -200	-5%	-$23.3K	0.04%	481
2018 Q4	$404K	Hold	3,710	–	–	0.05%	425
2018 Q3	$474K	Sell	3,710 -500	-12%	-$61.8K	0.05%	418
2018 Q2	$476K	Buy	4,210 +500	+13%	+$55K	0.06%	394
2018 Q1	$417K	Hold	3,710	–	–	0.05%	414
2017 Q4	$549K	Hold	3,710	–	–	0.07%	345
2017 Q3	$435K	Buy	+3,710	New	+$474K	0.06%	428
2017 Q2	–	Sell	-1,500	Closed	-$203K	–	872
2017 Q1	$203K	Hold	1,500	–	–	0.03%	681
2016 Q4	$215K	Buy	+1,500	New	+$192K	0.03%	643

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Wedbush Securities's UTHR Position: Q3 2020 in Review

Wedbush Securities sold out of United Therapeutics (UTHR) in Q3 2020, closing a stake of 2,310 shares — an estimated $280K sold.

Wedbush Securities first reported a position in UTHR in Q4 2016 and held it in 14 quarters. The position peaked at $549K in Q4 2017. 333 funds tracked by Wall St. Rank hold UTHR as of Q3 2020.

Wedbush Securities reported no remaining United Therapeutics position as of Q3 2020 after selling out during the quarter.
Wedbush Securities sold 2,310 United Therapeutics shares in Q3 2020, an estimated $280K.
Wedbush Securities first reported a position in United Therapeutics in Q4 2016 and held it in 14 quarters.
Wedbush Securities's United Therapeutics position peaked at $549K in Q4 2017.
333 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2020.

Based on Wedbush Securities's 13F filing for Q3 2020, filed 20 Oct 2020.